NCIC CLINICAL TRIALS GROUP

GASTROINTESTINAL DISEASE SITE COMMITTEE MEETING

AGENDA

Delta Chelsea Hotel, Toronto
Sunday, October 19, 2003 - 9:00 a.m. - 3:30 p.m.
Room: Churchill Ballroom A

Chair: Dr. Malcolm Moore

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Presenter(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 am</td>
<td><strong>WELCOME AND INTRODUCTION</strong></td>
<td>Dr. T. Fields</td>
</tr>
<tr>
<td>9:05 am</td>
<td><strong>CLOSED TRIALS: BRIEF COMMENTS</strong></td>
<td>Dr. T. Fields / Dr. C. O'Callaghan</td>
</tr>
<tr>
<td>9:20 am</td>
<td><strong>ACTIVE TRIALS</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CO.16</td>
<td>Dr. J. Couture</td>
</tr>
<tr>
<td></td>
<td>CO.17</td>
<td>Dr. D. Jonker</td>
</tr>
<tr>
<td></td>
<td>ES.2</td>
<td>Dr. Rebecca Wong</td>
</tr>
<tr>
<td></td>
<td>PA.2</td>
<td>Dr. S. Gallinger</td>
</tr>
<tr>
<td>10:10 am</td>
<td><strong>IND TRIALS UPDATE</strong></td>
<td>Dr. Ralph Wong</td>
</tr>
<tr>
<td></td>
<td>Update from IND Committee Meeting + Discussion of Future GI IND Trials</td>
<td></td>
</tr>
<tr>
<td>10:30 am</td>
<td><strong>REFRESHMENT BREAK</strong></td>
<td></td>
</tr>
<tr>
<td>10:50 am</td>
<td><strong>CONDUCTING CTSU TRIALS IN CANADA</strong></td>
<td>CTSU Representative</td>
</tr>
<tr>
<td>11:10 am</td>
<td><strong>CTSU TRIALS ENDORSED BY NCIC CTG</strong></td>
<td>Dr. Ralph Wong</td>
</tr>
<tr>
<td></td>
<td>PAC.1: (SWOG-S0205) – A Randomized Placebo Controlled Study of Cetuximab plus Gemcitabine in Patients with Locally Advanced, Unresectable or Metastatic Pancreatic Cancer</td>
<td></td>
</tr>
<tr>
<td></td>
<td>GAC.1: (CALGB-80101) – A Phase III Trial of Adjuvant Chemoradiation After Resection of Gastric or Gastroesophageal Adenocarcinoma</td>
<td></td>
</tr>
<tr>
<td>11:35 am</td>
<td><strong>CTSU STUDIES FOR CONSIDERATION</strong></td>
<td>Dr. C. O’Callaghan / Dr. M. Moore</td>
</tr>
<tr>
<td></td>
<td>How to determine CTSU endorsement and participation? - General Discussion</td>
<td></td>
</tr>
</tbody>
</table>

*continued . . .*
12:00 pm  LUNCH

1:00 pm  **PROSPECTIVE NCIC CTG TRIALS**

Multi-institutional randomized phase III Trial of Gemcitabine plus Capecitabine (GemCap) vs Gemcitabine alone in advanced unresectable biliary cancer  

Dr. J. Knox

A phase III randomized 2 x 2 factorial trial of early post-op RT vs standard timing of RT, with the addition of Avastin to bolus 5FU, in stage II-III rectal carcinoma patients not having pre-op RT  

Dr. F. Perera / Dr. C. Leighton

Randomized phase II trial of XELOX (capecitabine plus oxaliplatin) vs XELIRI (capecitabine plus irinotecan) in patients with recurrent or metastatic esophageal, gastroesophageal junction or gastric adenocarcinoma or undifferentiated carcinoma  

Dr. L. Siu

Canadian Uncommon Cancer Initiative (CUCI)  

Dr. P. Czaykowski

Phase II study of neoadjuvant 5-FU + Leucovorin + CPT-11 in patients with resectable liver metastases from colorectal adenocarcinoma  

Dr. O. Bathe

A randomized placebo controlled trial assessing Sandostatin LAR for diarrhea control in the adjuvant treatment of rectal cancer  

Dr. J. Kamra

EGFR and VEGF inhibition in metastatic hepatoma  

Dr. C. Cripps

Late additions…

2:10 pm  **GI INTERGROUP UPDATE**

Overview  

Dr. M. Moore

Colon Task Force  

Dr. T. Fields / Dr. M. Moore

Esophageal Task Force  

Dr. Rebecca Wong

Rectal Task Force  

Dr. J. Brierly

Pancreas Task Force  

Dr. M. Moore

2:30 pm  **REFRESHMENT BREAK**

2:50 pm  **ACTIVITIES OF THE GI DISEASE SITE COMMITTEE**  

Dr. M. Moore

3:00 pm  **DISCUSSION SESSION**

Oxaliplatin in Canada  

Dr. M. Moore

3:30 pm  **CLOSING REMARKS & ADJOURNMENT**  

Dr. M. Moore

3:35 pm  **CLOSED SESSION: GI EXECUTIVE MEETING**  

Dr. M. Moore

4:30 pm  **ADJOURNMENT**